Sio Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Sio Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-84,695	Closed	-$4.28M	–	89
2019 Q1	$4.28M	Buy	+84,695	New	+$3.77M	1.15%	32
2017 Q4	–	Sell	-63,835	Closed	-$3.81M	–	66
2017 Q3	$3.81M	Buy	+63,835	New	+$3.86M	1.98%	18

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sio Capital Management's EGRX Position: Q2 2019 in Review

Sio Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 84,695 shares — an estimated $4.28M sold.

Sio Capital Management first reported a position in EGRX in Q3 2017 and held it in 2 quarters. The position peaked at $4.28M in Q1 2019. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

Sio Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Sio Capital Management sold 84,695 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $4.28M.
Sio Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
Sio Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $4.28M in Q1 2019.
180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on Sio Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.